Eupraxia Pharmaceuticals Inc. (T:EPRX*CA)

Business Focus: Biotechnology & Medical Research (NEC)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEDAR
Company Contact
Address: 2067 Cadboro Bay Road, #201
Tel: N/A
IR: See website
Key People
Business Overview
Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company with a drug delivery technology platform. The Company's lead product candidate EP-104IAR, is developed for the treatment long-lasting pain relief for knee osteoarthritis (OA). In addition to EP-104IAR, Eupraxia is developing a pipeline of earlier-stage long-acting formulations. The Company's pipeline candidates include a range of drugs for indications such as post-surgical anesthetic (EP-105) and post-surgical site infections (EP-201). The Company is also engaged in the development of candidates to its pipeline including an internally developed oncology product. The Company is also engaged in developing a formulation of EP-104IAR for use in canine and equine OA.
Financial Overview
For the nine months ended 30 September 2021,Eupraxia Pharmaceuticals Inc revenues was not reported. Netloss increased from C$3.9M to C$19.3M. Higher net lossreflects Research and development increase from C$1.1M toC$7.9M (expense), Stock-based compensation increase fromC$168K to C$3.7M (expense), Loss on conversion of notes andspecial increase from C$0K to C$2.3M (expense).
Reporting Currency: Canadian Dollars
Enterprise value: $47.59M as of Sep 30, 2021
Annual revenue (TTM): $0.00M as of Sep 30, 2021
EBITDA (TTM): -$14.96M as of Sep 30, 2021
Net annual income (TTM): -$19.41M as of Sep 30, 2021
Free cash flow (TTM): -$11.61M as of Sep 30, 2021
Net Debt Last Fiscal Year: N/A
Shares outstanding: 14,242,595 as of Sep 30, 2021
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.